Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q4 2019 Results - Earnings Call Transcript
11:45pm, Wednesday, 26'th Feb 2020
Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q4 2019 Results - Earnings Call Transcript
BioMarin Pharmaceutical (BMRN) Q4 Earnings Top Estimates
05:35pm, Wednesday, 26'th Feb 2020
BioMarin (BMRN) delivered earnings and revenue surprises of 19.05% and -1.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BioMarin's Novel Treatment Promises to Disrupt Competitors
07:08am, Wednesday, 26'th Feb 2020
The gene therapy maker's novel medicine has the potential to take over a highly competitive market and offer growth opportunities for investors.
BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?
09:28am, Monday, 24'th Feb 2020
Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.
BioMarin (BMRN) Catches Eye: Stock Jumps 6.1%
08:59am, Monday, 24'th Feb 2020
BioMarin (BMRN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
07:05pm, Thursday, 20'th Feb 2020
The agency expects to make a decision by Aug. 21, 2020.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
12:31pm, Wednesday, 19'th Feb 2020
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Goldman Sachs Sets BioMarin Target 75% Above Current Price
03:29pm, Tuesday, 04'th Feb 2020
With sales of $1.6 billion over the past year, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will get a hefty revenue boost with the introduction of its hemophilia A therapy, which is expected later this
3 Top Biotech Picks for 2020
01:20pm, Monday, 20'th Jan 2020
These stocks could thump the broader markets this year.
BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy
04:58pm, Thursday, 16'th Jan 2020
If approved, Valrox could become the most expensive drug in the world.
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
08:33am, Tuesday, 14'th Jan 2020
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
These 3 Biotech Stocks Could Be Top Stocks in 2020
08:01am, Saturday, 11'th Jan 2020
Fast-approaching catalysts could make these biotech stocks top performers this year.
BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%
08:40am, Friday, 10'th Jan 2020
BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
5 Goldman Sachs Conviction List Stocks With Massive Upside Potential for 2020
07:15am, Friday, 10'th Jan 2020
With 2020 now rolling, and the first quarter in full swing, many investors are resetting for what could be a more volatile rest of the year as the ongoing trade issues and geopolitical instability in
BioMarin (BMRN) Upgraded to Strong Buy: Here's Why
12:00pm, Tuesday, 24'th Dec 2019
BioMarin (BMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
